Navigation Links
Sanofi Forms Partnership with UMass Boston with $1 Million Support of Student Success Program for STEM Education

Boston, Mass. (PRWEB) September 19, 2013

Sanofi and its Cambridge-based biotechnology company, Genzyme, today announced a new partnership and $1 million gift to support student success programs in the University of Massachusetts Boston’s College of Science and Mathematics (CSM). The announcement of the gift was made at the opening of Sanofi’s new R&D facility at 640 Memorial Drive in Cambridge, which will be focused on cancer research.

“We thank and recognize Sanofi and Genzyme for sharing our vision for student success in science, technology, engineering, and mathematics (STEM) and for their partnership with UMass Boston students and the future of Greater Boston,” said Chancellor J. Keith Motley.

“Supporting the Commonwealth's goal of continued leadership in scientific and technological innovation, CSM is providing its students with an outstanding academic experience that enhances their prospects for careers in STEM fields. This investment in UMass Boston students by Genzyme and Sanofi, which extends an existing partnership, represents an outstanding example of how collaboration between a public higher education institution and a major corporation can have a significant impact on developing a vibrant STEM workforce.”

Genzyme and Sanofi target their philanthropic giving toward areas of need in communities, with particular focus on science and education, including organizations that foster the next generation of diverse STEM leaders. The College of Science and Mathematics has developed a highly successful program for advancing student success in STEM majors. This program revamped advising, academic support, and orientation, and developed a learning community program as the centerpiece of this strategy. Retention in the program is more than 15 points above the college’s preexisting levels, with large increases of students remaining in STEM majors.

“This partnership means that together, we can make a major contribution to sustaining and enhancing the local R&D ecosystem and supporting our collective future by ensuring a steady supply of young people with advanced training and education,” said Christopher Viehbacher, Chief Executive Officer, Sanofi. “By supporting a vibrant life sciences community, we are also laying the foundation for the research that will drive future innovations for patients.”

“Increased access to STEM education is essential to Massachusetts’ future economic competitiveness, including our strength as a global leader in the life sciences,” said Governor Deval Patrick. “I thank Sanofi and Genzyme for the generous contribution to our UMass Boston students and efforts to ensure that our state’s STEM workforce pipeline remains strong.”

The gift from Sanofi and Genzyme marks the third significant philanthropic gift this year supporting CSM student success programs. Earlier this year, San Francisco-based software giant Oracle gave $300,000 to support student success efforts in CSM, and Ralph and Janice James pledged $1 million to support student success efforts campus-wide.

With Sanofi and Genzyme’s support, CSM Dean Andrew Grosovsky plans to expand the student success program and develop new opportunities for undergraduate and graduate research.

“We couldn’t be more excited and grateful for this partnership with Sanofi and Genzyme,” said Dean Grosovsky. “CSM has experienced dramatic increases in enrollment and is a minority-majority college with large numbers of first-generation and low-income students. Since the retention and academic performance has been so strong, we are on track to greatly increase the number and diversity of STEM graduates. These graduates will be competitive for admission to graduate or professional schools, or to enter the STEM workforce.”

About UMass Boston
Recognized for its reputation for innovative research addressing complex issues, the University of Massachusetts Boston, metropolitan Boston’s only public university, offers its diverse student population both an intimate learning environment and the rich experience of a great American city. UMass Boston’s ten colleges and graduate schools serve 16,000 students while engaging local, national, and international constituents through academic programs, research centers, and public service activities. To learn more about UMass Boston, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
2. Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security
3. U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios Novel Biologic Candidate for Pseudomonas aeruginosa
4. Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
5. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
6. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
7. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
8. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
11. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
Post Your Comments:
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):